£72.00

It has never been this cheap. We have no record of a lower price.

£72 today · cheaper than every other day in the last 3 months

Südwestdeutscher Verlag für Hochschulschriften Identifizierung + Charakterisierung von Seneszenzgenen

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 55 days · 55 data points (no recent data)

Historical
Generating forecast…
£72.00 £68.40 £69.84 £71.28 £72.72 £74.16 £75.60 23 July 2026 05 August 2026 19 August 2026 01 September 2026 15 September 2026
View at Amazon ↗

Price data last checked 36 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 55 days • 1 price levels

Days at Price
55 days 0 14 28 41 55 £72 Days at Price

Price Analysis

Most common price: £72 (55 days, 100.0%)

Price range: £72 - £72

Price levels: 1 different prices over 55 days

Description

Prädisponierend für die Entstehung eines Zervixkarzinoms ist die persistierende Infektion mit humanen Papillomaviren (HPV), insbesondere den Hochrisiko-Typen (HR) 16 und 18. Das Zervixkarzinom geht in der Regel aus einer prämalignen Neoplasie (cervical intraepithelial neoplasia, CIN) hervor. Zusätzlich zur Infektion mit einem HR-HPV Typ sind genetische Veränderungen der befallenen Zelle für die Tumorentstehung entscheidend. Ein Ziel der vorliegenden Arbeit war die spezifische Identifikation und Validierung putativer Tumorsuppressorgene auf den Chromosomen 4q und 10p, welche gegenüber CIN im Zervixkarzinom (CxCa) signifikant schwächer exprimiert werden. Im zweiten Teil wurden neun der 19 identifizierten Gene funktionell charakterisiert. Um den Gentransfer optimal zu gewährleisten, erfolgte die Etablierung einer Transduktionsmethode auf Basis von Lentiviren. Für die funktionellen Analysen wurden geeignete Zelllinien und primäre Zellen (Fibroblasten und Keratinozyten) stabil transduziert. Im Vordergrund stand die Induktion von Seneszenz durch Genkomplementation.

Product Specifications

Format
paperback
Domain
Amazon UK
Release Date
18 November 2012
Listed Since
22 November 2012

Barcode

No barcode data available

Similar Products You Might Like

Trends in Cervical Cancer
80% match

Trends in Cervical Cancer

£33.28 31 Aug 2026
Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer
80% match

Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer

Springer

£108.01 07 Aug 2026
Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer
80% match

Human Papillomavirus (HPV)-Associated Oropharyngeal Cancer

Springer

£108.01 06 Aug 2026
The Papillomaviruses
79% match

The Papillomaviruses

Springer

£108.01 08 Aug 2026
Infecção pelo papilomavírus humano nas mulheres do Burkina Faso: Caracterização dos genótipos de alto risco
79% match

Infecção pelo papilomavírus humano nas mulheres do Burkina Faso: Caracterização dos genótipos de alto risco

£77.00 15 Sep 2026
Human Papillomavirus Vaccines
78% match

Human Papillomavirus Vaccines

£60.00 23 Aug 2026
Molecular Determinants of Head and Neck Cancer (Current Cancer Research)
78% match

Molecular Determinants of Head and Neck Cancer (Current Cancer Research)

Humana

£109.08 29 Aug 2026
Molecular Determinants of Head and Neck Cancer (Current Cancer Research)
78% match

Molecular Determinants of Head and Neck Cancer (Current Cancer Research)

Humana

£105.00 15 Sep 2026
HPV and Cervical Cancer: Achievements in Prevention and Future Prospects
78% match

HPV and Cervical Cancer: Achievements in Prevention and Future Prospects

Springer

£108.01 06 Aug 2026
Papillomaviruses (Novartis Foundation Symposia)
77% match

Papillomaviruses (Novartis Foundation Symposia)

Wiley

Price unavailable
HPV and Cancer
77% match

HPV and Cancer

Springer

£107.11 15 Sep 2026
New Developments in Cervical Cancer Screening and Prevention
77% match

New Developments in Cervical Cancer Screening and Prevention

Wiley

Price unavailable
Cervical Cancer: Methods and Protocols: 1249 (Methods in Molecular Biology, 1249)
77% match

Cervical Cancer: Methods and Protocols: 1249 (Methods in Molecular Biology, 1249)

Humana

£54.38 31 Aug 2026
Genomische Analyse von DTCs bei Ösophaguskarzinompatienten: Ident. einer progn. relevanten DTC-Subpopulation und Etabl. der aCGH zur hochaufgelösten genomischen Einzelzellanalyse
77% match

Genomische Analyse von DTCs bei Ösophaguskarzinompatienten: Ident. einer progn. relevanten DTC-Subpopulation und Etabl. der aCGH zur hochaufgelösten genomischen Einzelzellanalyse

Südwestdeutscher Verlag für Hochschulschriften

£67.00 15 Sep 2026
Cervical Cancer: 70 (Current Topics in Pathology, 70)
77% match

Cervical Cancer: 70 (Current Topics in Pathology, 70)

Springer

£76.42 01 Sep 2026
HPV Infection in Head and Neck Cancer: 206 (Recent Results in Cancer Research, 206)
77% match

HPV Infection in Head and Neck Cancer: 206 (Recent Results in Cancer Research, 206)

Springer

£73.10 06 Aug 2026
Cervical Cancer: From Etiology to Prevention: 2 (Cancer Prevention-Cancer Causes, 2)
76% match

Cervical Cancer: From Etiology to Prevention: 2 (Cancer Prevention-Cancer Causes, 2)

Springer

£147.03 08 Aug 2026
Colposcopy of Female Genital Tract
76% match

Colposcopy of Female Genital Tract

Springer

£86.01 08 Aug 2026
Papillomaviruses and Human Disease
76% match

Papillomaviruses and Human Disease

Springer

£83.78 13 Sep 2026
Zervixkarzinom: Beiträge Zur Verhütung, Früherkennung Und Behandlung: 14 (Fortschritte Der Onkologie)
75% match

Zervixkarzinom: Beiträge Zur Verhütung, Früherkennung Und Behandlung: 14 (Fortschritte Der Onkologie)

De Gruyter

£117.50 15 Sep 2026
Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development (Current Clinical Oncology)
75% match

Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development (Current Clinical Oncology)

Springer

£72.63 05 Aug 2026
Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development (Current Clinical Oncology)
75% match

Gynecological Cancers: Genetic and Epigenetic Targets and Drug Development (Current Clinical Oncology)

Springer

£88.21 19 Aug 2026
Molecular Pathogenesis of Colorectal Cancer
75% match

Molecular Pathogenesis of Colorectal Cancer

Springer

£108.01 06 Aug 2026
From Pap Smears to HPV Vaccines: Evolution of the Cervical Cancer Prevention Industry (Obstetrics and Gynecology Advances)
75% match

From Pap Smears to HPV Vaccines: Evolution of the Cervical Cancer Prevention Industry (Obstetrics and Gynecology Advances)

£203.99 31 Aug 2026